Progressive neuronal cell loss in a small subset of brainstem and mesencephalic nuclei and
widespread aggregation of the α-synuclein protein in the form of Lewy bodies and Lewy …

… Merchant is the President/CEO of Chaperone Therapeutics, serves on the Scientific Advisory
Board of the Michael J. Fox Foundation, and consults for AbbVie, Acumen Pharmaceuticals …

The neurotransmitter glutamate is the primary excitatory neurotransmitter in mammalian
brain and is responsible for most corticocortical and corticofugal neurotransmission. …

Mutations in LRRK2 and GBA1 are common genetic risk factors for Parkinson’s disease (PD)
and major efforts are underway to develop new therapeutics that target LRRK2 or …

Human genetic variants predicted to cause loss-of-function of protein-coding genes (pLoF
variants) provide natural in vivo models of human gene inactivation and can be valuable …

Several studies indicate a role for the serotonin 2 subfamily (5-HT 2A , 5-HT 2B , 5-HT 2C ) in
mediation of fear and anxiety responses. The current study began to examine the effects of …

The Parkinson’s disease (PD) research field has seen the advent of several promising
biomarkers and a deeper understanding of the clinical features of the disease from the earliest …

Background Emerging evidence shows that α-synuclein seed amplification assays (SAAs)
have the potential to differentiate people with Parkinson's disease from healthy controls. We …

Alpha-synuclein seed amplification assays (αSyn-SAAs) are promising diagnostic tools for
Parkinson’s disease (PD) and related synucleinopathies. They enable detection of seeding-…

Parkinson's disease (PD) is a growing burden worldwide, and there is no reliable biomarker
used in clinical routines to date. Cerebrospinal fluid (CSF) is routinely collected in patients …